Previous 10 | Next 10 |
Pharma/biotech is the most attractive subsector. The most overvalued one is life science tools. IXJ: an alternative to XLV. 10 stocks cheaper than their peers in December. For further details see: IXJ: Healthcare Dashboard For December
Teleflex Incorporated has generally performed well over the past few years and that attractive performance resumed this year after a mixed 2020. The company's prospects are favorable, but this doesn't mean the company makes for a great buy today. In all, shares are probably more o...
Glenview Capital Management’s 13F portfolio value decreased from $5.96B to $5.46B this quarter. The number of positions decreased from 64 to 59. They increased Baxter International and Uber Technologies while decreasing ViacomCBS and dropping Walgreens Boots Alliance. The t...
Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatm...
Breast Cancer Index reaffirmed as a significant predictive and prognostic diagnostic tool to personalize extended endocrine decisions Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating that Breast Cancer IndexȒ...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced acquisition of Bolder Surgical, a privately held, U.S.-based company that provides advanced energy vessel sealing surgical devices. "The acquisition of Bolder Surgical will expand...
Stepped-up philanthropic commitment, made on Giving Tuesday, will deepen the Company’s impact on local communities where its employees develop medical innovations Hologic, Inc. (Nasdaq: HOLX), a global leader in medical technology with a primary focus on improving wom...
Hologic, Inc. (Nasdaq: HOLX) announced today that its three SARS-CoV-2 tests all detect the recently emerged Omicron variant of the coronavirus that causes COVID-19. Initially identified in South Africa and subsequently in a number of African, European and North American countries, the ...
Hologic has seen a strong 2021 as the pandemic has been with us longer than expected and certainly hope. While the 2022 guidance looks soft, exactly this reason will likely trigger a positive surprise. With excess earnings used to make bolt-on deals and cut debt, I remain upbeat h...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 10:30:04 ET BTIG analyst issues NEUTRAL recommendation for HOLX on July 30, 2024 08:28AM ET. The previous analyst recommendation was Neutral. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-07-30 09:30:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for HOLX on July 30, 2024 07:43AM ET. The previous analyst recommendation was Sector Perform. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus ...
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Y...